Ocumension Acquires Implant Therapy for Retina Diseases in $119 Million Deal
April 14, 2021 at 06:00 AM EDT
Shanghai Ocumension Therapeutics acquired Greater China rights to Alimera’s implant therapy for diabetic macular edema and other retina diseases in a $119 million agreement. Alimera is an Atlanta area company. Ocumension will develop Iluvien® 0.19mg fluocinolone acetonide intravitreal implant for use in Greater China. It made a $10 million equity investment in Alimera, paid $10 million upfront and will be responsible for up to $89 million in sales-based milestones. Ocumension will will also issue four-year warrants for 1 million of its shares to Alimera. More details.... Stock Symbol: (HK: 1477) Share this with colleagues: // //